Anji Pharmaceuticals is a clinical-stage biotechnology company developing innovative therapies targeting the NLRP3 inflammasome and related inflammatory pathways. Founded in 2016, the company has a unique approach that combines expertise in metabolic disease and neuroinflammation, with a particular focus on Parkinson's disease where metabolic dysfunction and inflammation intersect.
| Attribute | Value |
|---|---|
| Founded | 2016 |
| Headquarters | South San Francisco, California, USA |
| CEO | Dr. Raymond L. Hill |
| Funding | Series C ($85M, 2023) |
| Focus | NLRP3 inhibitors, metabolic inflammation |
| Stage | Phase 1/Preclinical |
Anji Pharmaceuticals was founded based on research from Stanford University and the University of Cambridge:
The company's name "Anji" reflects its mission to bring "calm" (anji in Chinese) to dysregulated immune responses.
Anji's platform targets both:
This dual focus provides unique insights into the relationship between systemic inflammation and brain inflammation.
Anji's approach recognizes the connection between metabolic dysfunction and PD:
| Program | Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| ANJ-905 | NLRP3 inhibitor | Parkinson's disease | Preclinical | IND-enabling |
| ANJ-750 | NLRP3 inhibitor | Type 2 diabetes | Phase 1b | Completed |
| ANJ-802 | NLRP3/TNFR dual | Inflammatory diseases | Discovery | Early stage |
| ANJ-950 | NLRP3/LRRK2 dual | Parkinson's disease | Discovery | Lead optimization |
ANJ-905 is Anji's lead Parkinson's disease program:
The program leverages learnings from ANJ-750 (diabetes) to optimize for CNS applications.
ANJ-950 represents Anji's innovative dual-target approach:
This program is in early discovery but represents a novel approach in the PD pipeline.
ANJ-750 (diabetes) has generated valuable human data:
This human data supports the rationale for NLRP3 inhibition in neuroinflammation.
Anji has established key partnerships:
| Round | Amount | Year | Investors |
|---|---|---|---|
| Series A | $20M | 2016 | Versant Ventures, Third Rock |
| Series B | $40M | 2019 | Google Ventures, Pfizer Ventures |
| Series C | $85M | 2023 | Andreessen Horowitz, RA Capital |
Anji occupies a unique position with metabolic + CNS expertise:
| Company | Focus | Anji Differentiation |
|---|---|---|
| Anji | Metabolic + CNS | Unique dual-expertise |
| Olacteant | Clinical data | Diabetes focus |
| NodThera | CNS only | Less metabolic expertise |
| Inception | CNS only | Earlier stage |
Anji's metabolic-to-CNS approach addresses a significant unmet need:
| Parameter | Value |
|---|---|
| PD patients with metabolic dysfunction | ~40% |
| Addressable market | $5-10B annually |
| Competitive advantage | Human data available |